Guggenheim Lowers Amgen Price Target to $340 Amid Growth Concerns

On May 4, Guggenheim lowered its price target for Amgen (AMGN) from $351 to $340 following Q1 2026 earnings results. The firm maintained a Neutral rating but cited near-term challenges including biosimilar competition and regulatory issues affecting key products like MariTide and TAVNEOS.

By David Moadel May 4, 2026 3 min read · Yahoo Finance · May 4, 2026, 14:50 UTC

Guggenheim Lowers Amgen Price Target to $340 Amid Growth Concerns

Tickers: $AMGN $LLY $NVDA $NVO

Topics: Biotech Earnings Stock Analysis

Read the full article at Yahoo Finance

More World news

Blackbaud Reports Third Quarter Revenue Growth and Strategic AI Integration Motley Fool · November 12, 2026, 17:53 UTC
Sprott Physical Copper Trust Reports Significant Increase in Q3 Net Income Seeking Alpha · November 12, 2026, 17:51 UTC
Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC